Ailte I, Chauhan SK, Prasmickaite L, Bassarova AV, Poissonnier A, Feenstra M, Nyakas M, Johannessen B, Ryder T, Hermann R, Frich L, Holth A, Inderberg EM, Jespersen H, Flørenes VA, Kyte JA, Mælandsmo GM, Egeland EV (2026)
CD38^hiCD19^dim cells in lymph nodes predict favorable prognosis in patients with stage III melanoma receiving adjuvant PD-1-blockade
Front Oncol, 16, 1815008
DOI 10.3389/fonc.2026.1815008, PubMed 42158424

Eide HA, Grut H, Jebsen P, Kyte JA, Bratland Å (2026)
Hyperfractionated reirradiation and PD-1 blockade in recurrent squamous cell head and neck carcinomas with poor prognosis, results from the REPORT-trial
Radiother Oncol, 219, 111514
DOI 10.1016/j.radonc.2026.111514, PubMed 41916446

Svalheim KG, Andresen NK, Bjerre C, Gilje B, Jakobsen EH, Falk RS, Naume B, Kaasa S, Kyte JA (2026)
Patient-reported outcomes from the randomized ALICE trial evaluating the addition of atezolizumab to anthracycline-based chemotherapy in metastatic triple-negative breast cancer
Breast, 86, 104704
DOI 10.1016/j.breast.2026.104704, PubMed 41581361